The human microbiome is no longer viewed as a passive collection of hitchhikers; it is recognized as a dynamic endocrine organ, a master regulator of immunity, and a frontier for novel therapeutics. Among the myriad of commensal bacteria inhabiting our mucosal surfaces, Prevotella histicola has emerged as a high-priority candidate in the development of Live Biotherapeutic Products (LBPs). As a Contract Research Organization (CRO) dedicated to the preclinical advancement of microbiome-based medicine, Creative Biolabs provides a comprehensive suite of services designed to bridge the gap between strain discovery and clinical validation.
By leveraging our state-of-the-art anaerobic cultivation platforms, sophisticated multi-omics pipelines, and specialized disease models, we empower pharmaceutical and biotech partners to unlock the full therapeutic potential of P. histicola. Our mission is to accelerate your path to the clinic with data-driven insights and rigorous preclinical evidence.
Overview: The Therapeutic Potential of Prevotella histicola
Prevotella histicola is a Gram-negative, anaerobic bacterium originally isolated from the human oral cavity, though its most significant therapeutic implications stem from its presence and activity in the gut. Unlike some members of the Prevotella genus that have been controversially linked to inflammation, P. histicola is increasingly identified as a "beneficial" commensal with potent immunomodulatory properties.
The core mechanism of P. histicola involves its ability to modulate the gut-immune axis. It is particularly adept at inducing the differentiation of regulatory T cells (Tregs) and suppressing the overproduction of pro-inflammatory cytokines such as IL-17 and IFN-γ. In the context of the modern "hygiene hypothesis," the loss of such commensals is linked to the rise of autoimmune and inflammatory conditions. Preclinical research has demonstrated that oral administration of specific P. histicola strains can restore mucosal barrier integrity and systemic immune homeostasis, making it a cornerstone of contemporary microbiome therapeutic research.
Comprehensive Preclinical Research & Production Services
Navigating the complexities of Live Biotherapeutic development requires a multidisciplinary approach. Our CRO offers a modular service framework tailored specifically for Prevotella histicola research, ranging from initial discovery to pilot-scale production.
In the early development stages, flexibility and speed are paramount. We provide specialized lab-scale production services to support research and preclinical trials. Our capacities include:
-
Microbial Freeze-dried Powder Production: Utilizing advanced lyophilization techniques to preserve the viability and metabolic activity of P. histicola.
-
Extracellular Vesicle (EV) Production: Research indicates that the secretome of P. histicola, including its EVs, plays a role in immunomodulation. We offer specialized isolation and purification of these vesicles.
-
Cell-free Probiotic Supernatant: Production of metabolic byproducts (postbiotics) for evaluating indirect therapeutic effects.
-
Targeted Isolation: We utilize selective media and anaerobic chamber technology to isolate P. histicola from complex human or animal samples.
-
Full Genome Sequencing (WGS): Utilizing long-read sequencing technologies to provide a complete circularized genome, identifying antibiotic resistance genes (ARGs) and virulence factors to meet regulatory safety requirements.
-
Metabolic Profiling: Analysis of short-chain fatty acid (SCFA) production and carbohydrate fermentative profiling.
In Vitro Immunomodulation & Functional Assays
Transforming P. histicola into a stable drug product requires sophisticated formulation science.
-
Enteric Coating & Encapsulation: Developing pH-responsive and colon-targeted release systems (e.g., alginate beads or pectin coatings) to ensure the bacteria survive gastric acidity.
-
Pre-formulation Analysis: Evaluating particle size, moisture content, and surface charge (zeta potential) to optimize dosage form design.
Premium Preclinical Products for Microbiome Research
To support your in-house research, we provide a catalog of high-quality biological materials and specialized reagents.
|
Product Name
|
Catalog No.
|
Target
|
Product Overview
|
Datasheet
|
Price
|
|
Prevotella histicola
|
LBST-009FG
|
Prevotella
|
Prevotella histicola is Gram-negative bacillus that are obligately anaerobic, vary in pigmentation and are non-motile.
|
Download
|
$1988.00
|
|
Prevotella histicola Genomic DNA
|
LBGF-0925-GF331
|
Prevotella DNA
|
This product contains high-quality, intact genomic DNA isolated from Prevotella histicola Genomic DNA. It is a purified and ready-to-use DNA sample, ideal for a wide range of molecular biology applications, including PCR, qPCR, and Next-Generation Sequencing.
|
Download
|
$1120.00
|
Research Applications: Targeting Disease with P. histicola
The research applications for P. histicola are expanding rapidly across various therapeutic areas. Our services focus on the following primary indications:
One of the most significant breakthroughs in P. histicola research is its role in the gut-brain axis. Research suggests that this strain can suppress Experimental Autoimmune Encephalomyelitis (EAE), the standard animal model for MS. We offer EAE mouse models coupled with high-resolution flow cytometry to track immune cell trafficking from the gut to the brain.
P. histicola has shown the ability to reduce the severity of collagen-induced arthritis. It works by decreasing gut permeability and modulating the systemic immune response that leads to joint destruction. Lowering of serum levels of anti-collagen antibodies and pro-inflammatory cytokines.
In models of colitis, P. histicola acts as a mucosal healer. It promotes the production of mucus and strengthens the intestinal wall, preventing the "leaky gut" syndrome that exacerbates Ulcerative Colitis and Crohn's disease.
Emerging research is investigating the role of this strain in preventing the autoimmune destruction of pancreatic beta cells. By modulating the gut immune environment during early life, P. histicola may provide a protective effect against the onset of Type 1 Diabetes.
Our Advantages: Why Partner With Us?
Choosing the right CRO is pivotal for the success of your Live Biotherapeutic program. Our facility stands out due to our deep specialization in anaerobic microbiology.
Microbiome Expertise
We are not a generalist CRO; our team consists of microbiologists and immunologists who specialize specifically in the Bacteroidetes phylum and Prevotella genus.
Integrated Multi-Omics
We don't just provide data; we provide insight. Our bioinformatics team integrates metagenomic, metatranscriptomic, and metabolomic data to give you a 360-degree view of how P. histicola interacts with the host.
End-to-End Support
From the initial "proof of concept" in a petri dish to the final regulatory-compliant preclinical dossier, we support every stage of the journey.
Cutting-Edge Technology
Our anaerobic workstations and automated liquid handling systems ensure high throughput without compromising the strict environmental conditions required for P. histicola viability.
Leading the Future of Live Biotherapeutics
The transition from viewing the microbiome as a "black box" to utilizing it as a source of precision medicine is the greatest shift in 21st-century healthcare. Prevotella histicola represents more than just a bacterium; it represents a new class of medicine that works in harmony with human biology.
As your dedicated research partner, we are committed to providing the scientific rigor, specialized equipment, and deep expertise necessary to transform this strain into a life-changing therapy. Whether you are a startup exploring the initial potential of the microbiome or an established pharmaceutical company expanding your LBP pipeline, our Prevotella histicola Research Service is your gateway to success. Together, we can redefine the treatment landscape for autoimmune and inflammatory diseases.
Would you like me to generate a more detailed experimental protocol for one of the specific disease models mentioned, such as the EAE model for Multiple Sclerosis?
Frequently Asked Questions (FAQs)
Is Prevotella histicola safe for human consumption?
As a naturally occurring commensal in the human oral and gut microbiota, it has a strong safety profile. However, for LBP development, we conduct rigorous safety assessments, including antibiotic susceptibility testing and toxicity studies in animal models to satisfy regulatory requirements.
How does P. histicola differ from Prevotella copri?
While they belong to the same genus, their roles are distinct. P. copri is often associated with high-fiber diets but has been occasionally linked to inflammation in specific genetic backgrounds. P. histicola, conversely, is more consistently recognized for its anti-inflammatory and immunomodulatory properties in therapeutic models.
Can you help with the regulatory filing for an Investigational New Drug (IND) application?
Yes. Our preclinical data packages are designed to meet the standards. We provide detailed reports on strain identity, purity, potency, and safety (tox) studies required for IND submissions.
What is the typical scale of your "small-scale" production?
Our lab-scale production is designed for flexibility, providing sufficient biomass for comprehensive animal studies and formulation development, typically ranging from bench-top fermenters to pilot-scale lyophilization batches.
